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bjectives We evaluated the effects of statin treatments for each component of coronary plaques.
ackground Effects of statin treatments on coronary plaques have not been sufﬁciently evaluated.
ethods One hundred patients without signiﬁcant lesion stenosis underwent baseline and 12-
onth follow-up virtual histology (VH) intravascular ultrasound (IVUS) studies and were treated with
tatin for 1 year. They were randomized to simvastatin (20 mg/day, n  50) or rosuvastatin (10 mg/
ay, n  50). With VH-IVUS, plaque was characterized as ﬁbrotic, ﬁbrofatty, dense calcium, and ne-
rotic core.
esults In overall patients, necrotic core volume signiﬁcantly reduced (15.7 to 13.7 mm3, p 
.010) and ﬁbrofatty plaque volume increased (4.3 to 5.5 mm3, p  0.006) after statin treatments for
year. There were no signiﬁcant differences of changes in either plaque component volume be-
ween simvastatin- and rosuvastatin-treated subgroups. In serial comparisons during 1-year follow-
p, simvastatin treatment did not achieve statistically signiﬁcant changes in ﬁbrofatty plaque (4.1 to
.1 mm3, p  0.131) and necrotic core volume (15.8 to 14.4 mm3, p  0.216). However, there was a
igniﬁcant decrease in necrotic core volume (15.5 to 13.0 mm3, p  0.015) and an increase in ﬁbro-
atty plaque volume (4.5 to 5.9 mm3, p  0.017) in the rosuvastatin-treated subgroup.
onclusions Serial volumetric VH-IVUS analysis showed that statin treatments might be associated
ith signiﬁcant changes in necrotic core and ﬁbrofatty plaque volume in overall patients. The
hanges in both plaques’ component volume were not statistically different between simvastatin-
nd rosuvastatin-treated subgroup. (J Am Coll Cardiol Intv 2009;2:679–88) © 2009 by the
merican College of Cardiology Foundation
rom the *Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seoul, Korea; and the
Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. This study was partly
upported by Cardiovascular Research Foundation, Seoul, Korea and a grant of the Korea Health 21 R&D Project, Ministry of
ealth & Welfare, Korea (0412-CR02-0704-0001)anuscript received March 23, 2009; accepted March 24, 2009.
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680tatin treatments have been reported to reduce major
ardiac events in patients with coronary artery disease in
everal clinical studies (1–3). Although long-term clinical
utcomes have been improved after statin therapy, previous
ngiographic studies showed only minimal changes in an-
iographic lumen dimension in target lesions in patients
ho were treated with statin (4,5). Several intravascular
ltrasound (IVUS) studies have demonstrated the benefits
f statin therapy to be involved in regression or no progres-
ion of coronary plaque size (6–8). However, conventional
ray-scale IVUS has significant limitations in accurately
See page 697
ssessing atheromatous plaque composition and identifying
vulnerable plaque before rupture of the vulnerable plaque
ccurs. These limitations of gray-scale IVUS have been
artially addressed by virtual histology (VH) IVUS, which
haracterizes plaques as calcified, fibrotic, fibrofatty, and
necrotic core (9–11). Rupture of
a vulnerable plaque and subse-
quent thrombus formation have
been reported to be the most
important mechanism leading to
an acute coronary syndrome
(ACS) in pathologic and au-
topsy studies (12,13). Statin
treatments have been regarded
as 1 of the most effective meth-
ods for stabilization of vulnera-
ble plaque and improvements of
long-term clinical outcomes in
patients with ACS (2,3,8,14).
However, effects of statin treat-
ments on coronary plaques in
VUS studies have not been sufficiently validated. Therefore
he primary aims of the present study were to evaluate, with
H-IVUS technology, the effects of statin treatments on
ach component of coronary plaques. We also evaluated,
econdarily, the impacts on each component of plaques
ccording to different types of statin treatment regimen.
ethods
tudy population. One hundred patients with de novo
onculprit/nontarget lesions were included in this random-
zed study at Asan Medical Center. These patients who
ere randomized to simvastatin (20 mg/day, n  50) or
osuvastatin (10 mg/day, n  50) treatment for 1 year
nderwent baseline and 12-month follow-up VH-IVUS
tudy. The inclusion criteria of this study were lesions
ithout significant stenosis by coronary angiogram (diam-
bbreviations and
cronyms
CS  acute coronary
yndrome
EM  external elastic
embrane
DL  high-density
ipoprotein
VUS  intravascular
ltrasound
DL  low-density
ipoprotein
&M  plaque and media
H  virtual histologyter stenosis 50%), lesions with a plaque burden 0.75 by ray-scale IVUS, and lesions located in 1 of 3 major
picardial arteries in which stent implantation was not
erformed. The exclusion criteria were severely calcific
esions, hemodynamically unstable patients, cardiogenic
hock, recommended coronary artery bypass graft surgery,
nd previous history of administration of lipid-lowering
gents including statin. During the 1-year follow-up, the
ccurrence of major adverse cardiac events including death
f any causes, acute myocardial infarction (elevation of the
reatine kinase-myocardial band fraction to a value 3 times
he upper limit of normal), and target lesion revasculariza-
ion (percutaneous or surgical intervention of these nonste-
otic lesions) was evaluated. This study was performed with
he patient’s written informed consent and approval of the
nstitutional review board. Changes () in lipid profiles,
-reactive protein, and VH-IVUS variables were calculated
s follow-up minus baseline values.
VUS imaging and analysis. Baseline and 1-year follow-up
H-IVUS examinations were performed before any inter-
ention and after intracoronary administration of 0.2 mg
itroglycerin with motorized transducer pullback system
0.5 mm/s). The 2.9-F IVUS imaging catheter (Eagle Eye,
olcano Corp., Rancho Cordova, California) incorporated a
0-MHz phased-array transducer.
Conventional gray-scale quantitative IVUS analyses were
erformed according to criteria of the clinical expert con-
ensus document on IVUS to include external elastic mem-
rane (EEM), lumen, and plaque & media (P&M) (P&M
EM  lumen) areas (15). Plaque burden was defined as
&M divided by EEM area.
Volumetric VH-IVUS analysis was performed along a
0-mm segment with 1-mm interval centered on the
inimal lumen area and was calculated with Simpson’s rule.
he VH-IVUS analysis classified color-coded tissue as
reen (fibrotic), yellow-green (fibrofatty), white (dense cal-
ium), and red (necrotic core) (9,10). The VH-IVUS
nalyses were reported in absolute amounts and as a per-
entage (relative amounts) of plaque volume. The study
opulations were also arbitrarily divided into 2 subgroups:
he subgroup with a decrease in necrotic core volume by
erial analysis in group 1 (Fig. 1), and the subgroup without
decrease in necrotic core volume in group 2.
tatistical analysis. Statistical analysis was performed with
PSS (SPSS Inc., Chicago, Illinois). Data are presented as
requencies or mean  SD. Comparison was performed
ith chi-square statistics or Fisher exact test and paired or
npaired Student t test or Mann-Whitney U test. Nonpara-
etric analysis with Wilcoxon signed rank test was also
one. Multiple stepwise logistic regression analysis was
erformed to assess independent clinical predictors for
ecrease in necrotic core volume by serial analysis. A p value
0.05 was considered statistically significant.
RB
w
i
t
m
c
t
i
1
g
T
m
v
t
d
s
o
s
E
4
2
p
b
T
s

v
a
t
t
a
c
m
s
d
b
.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 7 , 2 0 0 9 Hong et al.
J U L Y 2 0 0 9 : 6 7 9 – 8 8 Statin and Plaque Characteristics
681esults
aseline clinical characteristics are shown in Table 1. There
ere no significant differences of baseline clinical character-
stics between simvastatin- and rosuvastatin-treated pa-
ients. Compared with simvastatin-treated patients, 12-
onth follow-up total and low-density lipoprotein (LDL)
holesterol levels were significantly lower in rosuvastatin-
reated patients. No major adverse cardiac events occurred
n either group for 12-month follow-up. Baseline and
2-month follow-up and changes during 1-year follow-up
ray-scale and VH-IVUS analysis are shown in Table 2.
here were no significant differences of baseline and 12-
onth follow-up gray-scale and VH-IVUS variables in
olumetric analysis between simvastatin- and rosuvastatin-
reated patients. There were also no statistically significant
ifferences of changes in each plaque component between
imvastatin- and rosuvastatin-treated subgroups.
Serial changes of gray-scale and VH-IVUS variables in
Figure 1. A Decrease in Necrotic Core Volume After Statin Treatment
Typical example of a decrease in necrotic core volume by serial volumetric virt
and (B) 12-month follow-up gray-scale IVUS images. (C) Baseline and (D) 12-m
decreased from 2.3 mm2 (47%) baseline to 1.1 mm2 (24%) 12-month follow-upverall patients are shown in Table 3. Overall, there were aignificant changes in gray-scale IVUS plaque volumes:
EM volume (176.2  42.0 mm3 at baseline and 172.3 
1.6 mm3 at follow-up, p  0.001), P&M volume (89.8 
7.1 mm3 at baseline and 87.1  27.2 mm3 at follow-up,
 0.001), and lumen volume (86.4  23.4 mm3 at
aseline and 85.2  22.8 mm3 at follow-up, p  0.041).
he VH-IVUS analysis showed that necrotic core volume
ignificantly reduced (15.7  9.9 mm3 at baseline and 13.7
9.9 mm3 at follow-up, p  0.010) and fibrofatty plaque
olume significantly increased (4.3  3.5 mm3 at baseline
nd 5.5  4.0 mm3 at follow-up, p  0.006) after statin
reatments for 1 year. In the simvastatin-treated subgroup,
he changes in fibrofatty plaque (4.1  2.9 mm3 at baseline
nd 5.1  4.4 mm3 at follow-up, p  0.131) and necrotic
ore volume (15.8  11.3 mm3 at baseline and 14.4  10.5
m3 at follow-up, p  0.216) did not achieve statistical
ignificance (Table 2). However, there was a significant
ecrease in necrotic core volume (15.5  8.4 mm3 at
aseline and 13.0  9.4 mm3 at follow-up, p  0.015) and
stology (VH) intravascular ultrasound (IVUS) analysis is shown. (A) Baseline
follow-up VH-IVUS images. The amounts of necrotic core componentsual hi
onthn increase in fibrofatty plaque volume (4.5  4.0 mm3 at
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682aseline and 5.9  3.5 mm3 at follow-up, p  0.017) in the
osuvastatin-treated subgroup (Table 2).
Baseline clinical characteristics between group 1 and
roup 2 are shown in Table 4. A decrease in necrotic core
olume by serial analysis was observed in 27 (54%)
imvastatin-treated and 35 (70%) rosuvastatin-treated pa-
ients (p  0.099). Compared with the patients in group 2,
he patients in group 1 were significantly older and had
igher level of baseline high-density lipoprotein (HDL)-
holesterol. There were more male patients and rosuvastatin
reatments and higher level of 12-month follow-up HDL
holesterol in the patients in group 1. All clinical univariate
Table 1. Baseline Clinical Characteristics Between Simvastatin- and Rosuv
Simvast
No. of patients 50
Age (yrs) 58
Male sex 40 (80
Hypertension 22 (44
Diabetes mellitus 13 (26
Cigarette smoking 19 (38
Acute coronary syndrome 20 (40
C-reactive protein (mg/dl)
Baseline 0.17
12-month follow-up 0.12
Changes 0.05
Lipid proﬁles at baseline
Total cholesterol (mg/dl) 191
LDL cholesterol (mg/dl) 119
HDL cholesterol (mg/dl) 43
Triglycerides (mg/dl) 149
Lipid proﬁles at 12-month follow-up
Total cholesterol (mg/dl) 142
LDL cholesterol (mg/dl) 78
HDL cholesterol (mg/dl) 48
Triglycerides (mg/dl) 115
Changes of lipid proﬁles
∆ Total cholesterol (mg/dl) 49
∆ LDL cholesterol (mg/dl) 41
∆ HDL cholesterol (mg/dl) 6
∆ Triglycerides (mg/dl) 24
No. of diseased vessels
1 36 (72
2 8 (16
3 6 (12
Medications
Nitrates 46 (92
Calcium channel blocker 41 (82
Beta-blocker 40 (80
Angiotensin II receptor antagonist 14 (28
Angiotensin-converting enzyme inhibitor 11 (22
Values are n, mean SD, or n (%).
HDL high-density lipoprotein; LDL low-density lipoprotein.redictors for a decrease in necrotic core volume at a p 0.2 sevel were entered into the multiple logistic regression
odel; sex, age, types of statin treatment, and baseline and
2-month follow-up HDL-cholesterol level. The only in-
ependent clinical predictor for a decrease in necrotic core
olume was baseline HDL-cholesterol level (p  0.040,
dds ratio: 1.044, 95% confidence interval (CI): 1.002 to
.089) by multiple stepwise logistic regression analysis.
here was a significant linear correlation between baseline
DL-cholesterol level and change in necrotic core volume
p 0.030, r 0.217, 95% CI:0.293 to0.015) (Fig. 2).
In overall patients, compared with the patients in
roup 2, fibrotic and fibrofatty plaque volume were
in-Treated Patients
Rosuvastatin p Value
50
59 9 0.7
37 (74) 0.5
24 (48) 0.7
11 (22) 0.6
19 (38) 1.0
23 (46) 0.5
0.21 0.20 0.4
0.09 0.07 0.22
0.12 0.19 0.12
189 27 0.7
116 28 0.6
43 11 0.8
152 75 0.9
128 20 0.002
64 21 0.002
52 14 0.127
107 96 0.6
61 26 0.045
52 25 0.046
9 11 0.120
39 51 0.138
0.9
35 (70)
10 (20)
5 (10)
47 (94) 0.5
43 (86) 0.8
38 (76) 0.8
12 (24) 0.8
10 (20) 1.0astat
atin
10
)
)
)
)
)
0.22
0.12
0.22
34
30
10
69
22
20
12
50
30
26
10
40
)
)
)
)
)
)
)
)ignificantly smaller and necrotic core volume was signif-
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683cantly greater in the patients in group 1 in baseline
H-IVUS study. In 12-month follow-up study, however,
brofatty plaque volume was significantly greater and
ecrotic core volume was significantly smaller in the
atients in group 1 (Table 5).
Serial changes of gray-scale and VH-IVUS variables in
Table 2. Gray-Scale and Virtual Histology Intravascular Ultrasound Analysis
Simva
Baseline
External elastic membrane volume (mm3) 173.5
Lumen volume (mm3) 85.2
Plaque volume (mm3) 88.3
Absolute volume (mm3)
Fibrotic 25.6
Fibrofatty 4.1
Dense calcium 6.5
Necrotic core 15.8
Percentages (%)
Fibrotic 50
Fibrofatty 9
Dense calcium 12
Necrotic core 29
1-yr follow-up
External elastic membrane volume (mm3) 169.6
Lumen volume (mm3) 83.3
Plaque volume (mm3) 86.3
Absolute volume (mm3)
Fibrotic 25.6
Fibrofatty 5.1
Dense calcium 6.2
Necrotic core 14.4
Percentages (%)
Fibrotic 52
Fibrofatty 10
Dense calcium 11
Necrotic core 26
Changes between baseline and 1-yr follow-up
∆ External elastic membrane volume (mm3) 3.9
∆ Lumen volume (mm3) 1.9
∆ Plaque volume (mm3) 1.8
Absolute volume (mm3)
∆ Fibrotic 0.0
∆ Fibrofatty 1.0
∆ Dense calcium 0.3
∆ Necrotic core 1.4
Percentages (%)
∆ Fibrotic 2
∆ Fibrofatty 2
∆ Dense calcium 1
∆ Necrotic core 3
*p  0.001; †p  0.01; ‡p  0.05; §p  0.131; ¶p  0.216; p  0.017; and #p  0.015, compareroups 1 and 2 are also shown in Table 5. In group 2, there aere no significant changes of P&M volume; reduction of
EM volume resulted in subsequent reduction of lumen
olume in serial gray-scale IVUS analysis. Fibrotic and
brofatty plaque volume significantly reduced (30.5  14.4
m3 to 25.6  11.4 mm3, p  0.001 and 6.1  4.0 mm3
o 4.3  2.6 mm3, p  0.01, respectively); dense calcium
een Simvastatin- and Rosuvastatin-Treated Patients
Rosuvastatin p Value
179.1 46.6 0.5
87.6 26.2 0.6
91.5 27.5 0.5
28.2 14.4 0.3
4.5 4.0 0.5
6.8 6.4 0.8
15.5 8.4 0.9
52 12 0.5
8 5 0.3
12 7 0.9
29 10 0.9
175.0 45.9* 0.5
87.2 25.7 0.4
87.8 27.8† 0.8
27.2 12.9 0.5
5.9 3.5 0.3
7.0 9.3 0.6
13.0 9.4# 0.5
53 12 0.7
12 7* 0.22
11 8 1.0
24 10† 0.22
4.2 6.6 0.8
0.4 7.0 0.18
3.6 7.2 0.16
1.0 7.9 0.6
1.4 4.0 0.7
0.2 9.5 0.8
2.5 7.0 0.5
1 11 0.7
4 8 0.09
0 7 0.9
5 12 0.3
aseline.Betw
statin
37.1
20.4
26.9
12.7
2.9
6.3
11.3
16
6
10
11
37.2*
19.5†
26.8‡
11.6
4.4§
6.2
10.5¶
12
6
8
10
6.0
4.0
5.7
8.8
4.7
5.1
8.1
16
8
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684m3 to 7.5  6.4 mm3, p  0.05, and 12.7  9.4 mm3 to
7.9  11.8 mm3, p  0.001, respectively). In group 1,
here were no significant changes of lumen volume; reduc-
ion of P&M volume was associated with subsequent
eduction of EEM volume in serial gray-scale IVUS anal-
sis. Fibrotic and fibrofatty plaque volume significantly
ncreased (24.7 12.6 mm3 to 26.9 12.6 mm3, p 0.05,
nd 3.2  2.5 mm3 to 6.3  4.4 mm3, p  0.001,
espectively); there were no significant changes of dense
alcium; necrotic core volume significantly decreased (17.5
9.8 mm3 to 11.2  7.6 mm3, p  0.001). There was a
ignificant linear correlation between the change in necrotic
ore volume and the change in P&M volume (p  0.001,
 0.329, 95% CI: 0.162 to 0.600) (Fig. 3) and the change
n lumen volume (p 0.001, r 0.412, 95% CI:0.787 to
0.304). However, the changes in necrotic core volume did
ot correlate with the changes in EEM volume (p  0.9,
 0.010, 95% CI: 0.253 to 0.229).
iscussion
n this randomized study of 100 patients who were treated
ith statin, statin treatments might be involved in signifi-
ant changes of plaques component volume. The changes in
laques component volume were not different between
imvastatin- and rosuvastatin-treated subgroups. Baseline
DL-cholesterol level was the only independent clinical
redictor for a decrease in necrotic core volume and was
ignificantly correlated with the change in necrotic core
olume. Although there were no significant changes of
&M volume in the patients without a decrease in necrotic
ore volume, there was a significant reduction in P&M
olume in the patients with a decrease in necrotic core
olume in serial gray-scale IVUS analysis. Serial volumetric
H-IVUS analysis showed that there was a significant
Table 3. Gray-Scale and Virtual Histology Intravascular Ultrasound Analysis
Baseline
External elastic membrane volume (mm3) 176.2 42
Lumen volume (mm3) 86.4 23
Plaque volume (mm3) 89.8 27
Absolute volume (mm3)
Fibrotic 26.9 13
Fibrofatty 4.3 3.
Dense calcium 6.7 6.
Necrotic core 15.7 9.
Percentages (%)
Fibrotic 51 14
Fibrofatty 8 5
Dense calcium 12 9
Necrotic core 29 11ecrease in fibrotic and fibrofatty plaque volume and an (ncrease in dense calcium and necrotic core volume in the
atients without a decrease in necrotic core volume. How-
ver, fibrotic and fibrofatty plaque volume significantly
ncreased and necrotic core volume significantly decreased
n the patients with a decrease in necrotic core volume.
The MIRACL (Myocardial Ischemia Reduction with
ggressive Cholesterol Lowering) study in 3,086 patients
ith ACS showed that lipid-lowering therapy with atorv-
statin, 80 mg/day, reduces early, recurrent ischemic events
2). The PROVE IT–TIMI 22 (PRavastatin Or atorVas-
atin Evaluation and Infection Therapy–Thrombolysis in
yocardial Infarction 22) study in 4,162 patients with ACS
eported that an intensive lipid-lowering statin regimen
atorvastatin, 80 mg/day) provides greater protection against
eath or major cardiovascular events than a standard regi-
en (pravastatin, 40 mg/day) (3). These clinical benefits of
tatin might be partially related to the result of a benefit in
tabilizing vulnerable plaques with the early and intensive
reatment after the acute event in patients with ACS, who
ave a culprit lesion and frequently additional multiple
ulnerable plaques as well (3).
The ASTEROID trial (A Study To Evaluate the Effect
f Rosuvastatin on IVUS-Derived Coronary Atheroma
urden), in 349 patients who had serial IVUS examinations,
howed that very high-intensity statin therapy with rosuv-
statin 40 mg/day achieved an average LDL-cholesterol of
0.8 mg/dl and increased HDL-cholesterol by 14.7%,
esulting in significant regression of coronary atherosclerosis
6). The REVERSAL (Reversal of Atherosclerosis with
ggressive Lipid Lowering) trial, in 502 patients who had
erial IVUS examinations, reported that compared with
aseline values, patients treated with atorvastatin (80 mg/day)
ad no change in atheroma burden, whereas patients treated
ith pravastatin (40 mg/day) showed progression of coro-
ary atherosclerosis (7). Because the previous IVUS studies
een Baseline and 1-Yr Follow-Up in Overall Patients
1-Yr Follow-Up p Value
172.3 41.6 0.001
85.2 22.8 0.041
87.1 27.2 0.001
26.4 12.2 0.5
5.5 4.0 0.006
6.6 7.9 0.9
13.7 9.9 0.010
52 12 0.21
11 7 0.001
11 8 0.6
25 10 0.002Betw
.0
.4
.1
.5
5
3
96,7) were performed with gray-scale IVUS technology,
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685etection of change of each plaque composition was very
ifficult. However, the present study showed that statin
reatment might result in changes of plaque composition
significant reduction in necrotic core volume and increase
n fibrofatty plaque volume) by VH-IVUS analysis as well as
eduction of P&M volume by gray-scale IVUS analysis. In
iewpoints of achievement of Adult Treatment Panel III
uideline LDL-cholesterol goals, efficacy of 10 mg of
osuvastatin was comparable to that of 20 mg of atorvastatin
nd 40 mg of simvastatin (16). The changes in plaques
omponent volume were not different between simvastatin-
nd rosuvastatin-treated subgroups in this serial VH-IVUS
tudy. Rosuvastatin, 10 mg, and simvastatin, 20 mg, were
Table 4. Baseline Clinical Characteristics of Patients With Versus Without
A
No
No. of patients 38
Age (yrs) 56 11
Male sex 33 (87)
Hypertension 20 (53)
Diabetes mellitus 7 (18)
Cigarette smoking 16 (42)
Acute coronary syndrome 18 (47)
Types of statin used
Simvastatin 23 (46)
Rosuvastatin 15 (30)
C-reactive protein (mg/dl)
Baseline 0.17 0.16
12-month follow-up 0.10 0.08
Changes 0.07 0.15
Lipid proﬁles at baseline
Total cholesterol (mg/dl) 191 26
LDL cholesterol (mg/dl) 120 25
HDL cholesterol (mg/dl) 40 10
Triglycerides (mg/dl) 154 74
Lipid proﬁles at 12-month follow-up
Total cholesterol (mg/dl) 133 22
LDL cholesterol (mg/dl) 72 22
HDL cholesterol (mg/dl) 48 10
Triglycerides (mg/dl) 100 42
Changes of lipid proﬁles
∆ Total cholesterol (mg/dl) 58 20
∆ LDL cholesterol (mg/dl) 48 17
∆ HDL cholesterol (mg/dl) 7 8
∆ Triglycerides (mg/dl) 33 37
No. of diseased vessels
1 29 (76)
2 7 (18)
3 2 (5)
Values are n, mean SD, or n (%).
HDL high-density lipoprotein; LDL low-density lipoprotein.rescribed and compared in this study because both statin soses are initially recommended for treatment of patients
ith coronary artery disease in Korea. The LDL-cholesterol
evel decreased from 119 to 78 mg/dl in the simvastatin-
reated subgroup and 116 to 64 mg/dl in the rosuvastatin-
reated subgroup. Follow-up LDL-cholesterol reached ap-
roximately 70 mg/dl in both statin groups of this study,
hich are recommended level in patients with ACS by
ecent Adult Treatment Panel III guideline (17). Without
eed for statin dose adjustments, LDL-cholesterol level was
ell-controlled in all patients during 1-year follow-up in
his study.
With gray-scale IVUS, recent meta-analysis of the stud-
es assessing temporal changes in coronary plaque volume
rease in Necrotic Core Volume
se in Necrotic Core Volume
Yes p Value
62
60 9 0.041
44 (71) 0.067
26 (42) 0.3
17 (27) 0.3
22 (36) 0.5
25 (37) 0.5
0.099
27 (54)
35 (70)
0.23 0.27 0.21
0.11 0.14 0.7
0.12 0.28 0.3
189 34 0.8
115 31 0.4
45 10 0.037
148 71 0.7
136 22 0.6
70 21 0.6
52 14 0.073
118 91 0.27
54 33 0.5
46 31 0.6
7 12 0.9
31 50 0.8
0.35
42 (68)
11 (18)
9 (14)a Dec
Decreahowed that statin therapy, particularly when achieving the
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686arget LDL level (100 mg/dl), seems to promote a signifi-
ant regression of IVUS-measured coronary plaque volume
18). We also reported similar results: 1) follow-up LDL
Figure 2. Baseline HDL-Cholesterol Level Versus Necrotic Core Volume
The correlation between baseline high-density lipoprotein (HDL) cholesterol
level and change in necrotic core volume is shown (p  0.030, r  0.217,
95% conﬁdence interval: 0.293 to 0.015).
Table 5. Gray-Scale and Virtual Histology Intravascular Ultrasound Analysis
N
Baseline
External elastic membrane volume (mm3) 183.4
Lumen volume (mm3) 91.8
Plaque volume (mm3) 91.6
Absolute volume (mm3)
Fibrotic 30.5
Fibrofatty 6.1
Dense calcium 5.6
Percentages (%)
Fibrotic 57
Fibrofatty 11
Dense calcium 9
1-yr follow-up
External elastic membrane volume (mm3) 180.0
Lumen volume (mm3) 88.6
Plaque volume (mm3) 91.0
Absolute volume (mm3)
Fibrotic 25.6
Fibrofatty 4.3
Dense calcium 7.5
Percentages (%)
Fibrotic 48
Fibrofatty 8
Dense calcium 13*p 0.01; †p 0.001; ‡p 0.05 compared with baseline.holesterol level was the only independent predictor for 
ean P&M area; and 2) the cutoff value for no change or a
laque regression was follow-up LDL-cholesterol 100
g/dl (19). However, because of the intrinsic limitations of
ray-scale IVUS, the previous studies can find only the
redictors for changes in overall plaque size (plaques regres-
ion or progression), not the predictors for changes in
pecific plaque composition. The published IVUS data
bout the predictors for changes in necrotic core size are
ery limited. In this study, baseline HDL-cholesterol level
as the only independent clinical predictor for a decrease in
ecrotic core volume by multiple stepwise logistic regression
nalysis. However, its power of positive correlation as an
ndependent predictor (p  0.040, odds ratio: 1.044, 95%
I: 1.002 to 1.089) was very weak. There was a tendency
hat a decrease in necrotic core volume was more frequently
bserved in the rosuvastatin-treated subgroup than in the
imvastatin-treated subgroup (70% vs. 54%, p  0.099);
owever, statistical significance was not achieved. There
ere no significant differences of baseline and follow-up
DL-cholesterol level in the subgroup with versus the
ubgroup without a decrease in necrotic core volume. These
ndings might suppose that, whereas the LDL-cholesterol
tients With Versus Without a Decrease in Necrotic Core Volume
ecrease in Necrotic Core Volume
Yes p Value
172.0 41.2 0.19
83.1 23.3 0.072
88.9 26.7 0.6
24.7 12.6 0.035
3.2 2.5 0.001
7.3 6.3 0.202
47 14 0.001
6 4 0.001
13 9 0.009
167.8 41.1† 0.169
83.2 22.7 0.3
84.7 26.6† 0.26
26.9 12.6‡ 0.6
6.3 4.4† 0.006
6.1 8.7 0.4
55 10† 0.004
13 7† 0.001
10 7* 0.108in Pa
A D
o
42.8
22.8
28.1
14.4
4.0
6.2
11
6
7
41.9*
22.8†
28.1
11.4†
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14†
5*
8†
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687evel is more significantly involved in changes in gross
laque size, the HDL-cholesterol level has a more specific
ole in changes in particular plaque components size (i.e.,
eduction of necrotic core). Although there are no available
ata that reduction in necrotic core size means plaques
tabilization or improved long-term clinical outcomes, re-
uction in necrotic core size might be 1 of several require-
ents for plaques stabilization. Therefore, we divided the
tudy populations into 2 subgroups: the patients with versus
ithout a decrease in necrotic core volume by serial analysis.
lthough significant changes in P&M volume did not occur
n the subgroup without a decrease in necrotic core volume,
here were significant reductions of P&M volume in the
ubgroup with a decrease in necrotic core volume. Signifi-
ant linear correlation between the change in necrotic core
olume and the change in P&M volume (p  0.001, r 
.329) suggested that plaque regression might result partly
rom decrease in necrotic core. However, the relations
etween a decrease in necrotic core size and plaques stabi-
ization or improved long-term clinical outcomes will be
urther evaluated in more studies with larger study popula-
ions and longer follow-up durations.
tudy limitations. This was an open-label trial without
asking without nonblinded IVUS analysis. This study has
he characteristics of an exploratory nature to analyze the
mounts of changes in each plaques component volume
fter statin treatment. The data in this study will be useful
o generate hypotheses in randomized clinical outcomes
Figure 3. Necrotic Core Volume Versus P&M Volume
The correlation between the change in necrotic core volume and the
change in plaque & media (P&M) volume is shown (p  0.001, r  0.329,
95% conﬁdence interval: 0.162 to 0.600).tudies using VH-IVUS.onclusions
erial volumetric VH-IVUS analysis showed that statin
reatments might have significant impacts on coronary
laques components in overall patients. The changes in
laques component volume were not statistically different
etween simvastatin- and rosuvastatin-treated subgroups.
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